Dr. Peter Olofsson-Sahl is one of the founders of Redoxis and served as CEO from 2007 to 2016. He brings extensive experience from academia, biotechnology, and innovation-driven company building.
Peter is Associate Professor in Medicine at University West and holds a PhD from Lund University. In addition, he has a Bachelor’s degree in Business Finance and an Executive MBA from the School of Business, Economics and Law at the University of Gothenburg.
Since 2015, Peter has served as an expert evaluator and monitor for the European Research and Innovation Councils as well as for the Danish and Norwegian Research Councils. He has also contributed as an external business advisor at Sahlgrenska Science Park and GU Ventures.
Peter is currently CEO and board member of ProNoxis, Inexius, and the startup company Inicure, all focused on the development of small-molecule therapies for inflammatory and infectious diseases. Earlier in his career, he held research positions in the biotechnology industry, including at Arexis and Biovitrum (publ).
